A content analysis published in the Journal of General Internal Medicine, “A claim that was objectively false by directly contradicting evidence, or lacking any evidence to support it.” Several U.S. laws go into defining and governing misleading marketing. The Federal Trade Commission Act prohibits deceptive advertising, meaning claims must be truthful and backed by evidence.
The Lanham Act allows companies to sue competitors for false advertising that causes harm. The Food, Drug, and Cosmetic Act bans false or misleading labels on drugs and medical devices. The Affordable Care Act requires transparency in health insurance marketing. HIPAA restricts marketing using patient information without consent. The CAN SPAM Act prevents deceptive email marketing.
What does misleading marketing look like in healthcare?
Misleading marketing in healthcare takes many forms. It often exaggerates the benefits of treatments or downplays their risks. Advertisements may claim that a product can deliver results that are unrealistic or unsupported by scientific evidence. For example, a supplement might be promoted as a miracle cure for a serious condition without any credible research backing the claim. Misleading marketing can also involve using complex scientific language or endorsements from so called experts to create an illusion of credibility.
Another common tactic is using testimonials or success stories that don’t reflect typical outcomes. Companies might present a few exceptional cases to imply that everyone will experience similar results, even though most people won’t. Misleading marketing can also occur when companies fail to disclose necessary information, such as potential side effects or limitations of a treatment. By omitting these details, they give a false impression of the product’s safety and effectiveness.
The consequences of misleading claims in a healthcare setting
When patients believe false claims, they may choose ineffective or unsafe treatments, which can worsen their health. It leads to more severe health issues and sometimes even life threatening situations. According to a study on misleading marketing published in the International Journal of Environmental Research and Public Health, “...misleading advertising is essentially characterized by inducing error or deception in the possible acceptor of a contract, in such a way that the principle of good contractual faith is violated, which must prevail in every legal relationship.”
The trickle down effects include financial loss as patients waste money on ineffective treatments. It also causes a loss of trust in healthcare providers, making people skeptical of legitimate medical advice.
The real world examples of misleading marketing in healthcare
In the OxyContin scandal, Purdue Pharma marketed OxyContin as a safer, less addictive opioid, which wasn’t true. They downplayed its risks, convincing doctors and patients that it was a better option for pain management. It led to widespread addiction, fueling the opioid crisis in the U.S. The company's deceptive claims caused immense harm, resulting in lawsuits and billions in settlements. The case shows how misleading marketing can have devastating real world consequences.
MyMedicalRecords, Inc., a company offering online personal health records, was accused by the Federal Trade Commission (FTC) of falsely marketing its services as providing HIPAA compliant protections for sensitive health information. The company claimed its service met the privacy and security requirements of HIPAA, but it did not implement sufficient safeguards. The FTC reached a settlement with the company, which included a monetary judgment and prohibitions against making false claims about the privacy and security of health information.
Practice Fusion, an electronic health records company, was fined by the FTC for deceptive marketing practices involving the use of patient data. The company collected and shared sensitive health information without proper patient consent, despite claiming to be HIPAA compliant. The FTC settlement required Practice Fusion to obtain patient authorization before using their data for marketing purposes, and they faced ongoing scrutiny to ensure compliance with privacy regulations.
The legislation that governs it
- Federal Trade Commission Act (FTC Act): The FTC has the authority to investigate and penalize companies that make false health claims, such as advertising a product as a cure without scientific backing. The FTC often targets misleading claims about supplements, weight loss products, and alternative therapies, ensuring that false or exaggerated health benefits do not deceive consumers.
- Lanham Act: The Lanham Act (Section 43(a)) addresses false advertising as a form of unfair competition. It allows businesses to sue competitors for making misleading claims that misrepresent their products or services. In healthcare, if a company falsely advertises the effectiveness of its drug or treatment, a competitor can take legal action, arguing that these misleading claims harm their business.
- Food, Drug, and Cosmetic Act (FDCA): The FDCA, enforced by the FDA, regulates the labeling and advertising of drugs, medical devices, and cosmetics (Section 502). It prohibits false or misleading claims about the safety or effectiveness of these products. For example, if a pharmaceutical company markets a drug with exaggerated benefits or minimizes risks without proper evidence, the FDA can take action, including issuing warnings, requiring label changes, or even recalling the product.
- Affordable Care Act (ACA): The ACA includes provisions that promote transparency and prevent deceptive practices in health insurance marketing (Section 1311). Insurers must clearly present information about their plans, ensuring that consumers understand what they are purchasing. Misleading claims about coverage, benefits, or costs can lead to regulatory penalties. The ACA helps protect consumers from being misled about their healthcare coverage options.
- Health Insurance Portability and Accountability Act (HIPAA): HIPAA primarily focuses on patient privacy, but it also impacts healthcare marketing. HIPAA restricts how healthcare providers and insurers can use and disclose protected health information (PHI) for marketing purposes without patient consent. For example, if a hospital wants to send marketing materials to patients using their health information, HIPAA requires that they first obtain explicit permission. Misleading marketing that involves the misuse of patient data can result in HIPAA violations and penalties.
- CAN SPAM Act: The CAN SPAM Act governs email marketing, including in the healthcare sector. This law requires transparency in email communications, prohibiting misleading subject lines or deceptive content. For healthcare providers or companies, this means they must be clear and honest in their email marketing, ensuring that recipients are not misled by false claims or hidden terms. Violations of the CAN SPAM Act can lead to fines and legal action.
The consequences
- FDA ordered product recalls: If a healthcare organization makes false claims about a drug or medical device, the FDA can order a recall of the product. It can lead to financial losses due to unsold inventory, logistical costs of the recall, and potential lawsuits from affected patients.
- FTC penalties and corrective advertising: The Federal Trade Commission can impose monetary fines on organizations for deceptive advertising. Additionally, the FTC may require the organization to run corrective advertising, publicly admitting to their misleading claims and clarifying the truth.
- Medicare/Medicaid exclusion: For organizations involved in false advertising that impacts federally funded healthcare programs, such as Medicare or Medicaid, there is a risk of being excluded from these programs.
- Class action lawsuits: Misleading claims can lead to class action lawsuits from groups of patients who were harmed by the false advertising. It results in legal costs as well as large settlements that can be financially crippling to the organization.
- State attorney general investigations: Misleading marketing claims can prompt investigations by state attorneys general, leading to multistate legal actions. These investigations often result in settlements or fines, along with requirements to change marketing practices and submit to ongoing monitoring.
- Revocation of accreditation: If a healthcare organization’s misleading marketing practices come to light, accrediting bodies like the Joint Commission may revoke the organization’s accreditation. The loss can lead to reduced patient trust, lower patient volumes, and difficulties in securing contracts with insurers.
- Civil monetary penalties for HIPAA violations: If misleading marketing involves improper use of protected health information (PHI) without proper consent under HIPAA, the organization can face civil monetary penalties. These penalties can range from thousands to millions of dollars, depending on the severity and nature of the violation.
- Disqualification from federal contracts: Healthcare organizations that engage in misleading marketing practices may be disqualified from bidding on or renewing federal contracts, such as those with the Department of Veterans Affairs or the Department of Defense.
See also: HIPAA Compliant Email: The Definitive Guide
FAQs
What is HIPAA?
HIPAA is a U.S. law that protects the privacy and security of patients' health information.
Who enforces HIPAA?
The U.S. Department of Health and Human Services (HHS) enforces HIPAA, specifically through its Office for Civil Rights (OCR).
What is the function of the FTC?
The Federal Trade Commission protects consumers by preventing deceptive, unfair, or fraudulent business practices, including in healthcare marketing.